A comparison of iPLEDGE requirements to risk mitigation programs for isotretinoin in other countries and to other teratogenic medications in the United States.

Nikita Menta Nidhi Shah A Yasmine Kirkorian

J Am Acad Dermatol

The George Washington University School of Medicine and Health Sciences, Department of Dermatology, Washington, DC 20052; Children's National Hospital, Division of Dermatology, Washington, DC 20010.

Published: January 2025

Download full-text PDF	Source
http://dx.doi.org/10.1016/j.jaad.2024.12.039	DOI Listing

Publication Analysis

Top Keywords

comparison ipledge

ipledge requirements

requirements risk

risk mitigation

mitigation programs

programs isotretinoin

isotretinoin countries

countries teratogenic

teratogenic medications

medications united

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!